Major Depressive Disorder
|
0.360 |
Biomarker
|
disease |
PSYGENET |
The steady-state plasma concentrations of imipramine and desipramine were measured after a more than 2-week treatment with 0.39 to 1.39 mg/kg/day of imipramine hydrochloride in 28 Japanese patients with major depression who had been phenotyped simultaneously with mephenytoin (for CYP2C19-related status) and with metoprolol (for CYP2D6-related status) before initiating the antidepressant therapy.
|
8835703 |
1996 |
Major Depressive Disorder
|
0.360 |
Biomarker
|
disease |
PSYGENET |
In 181 subjects with major depressive disorder, drug doses were recorded, imipramine and desipramine plasma concentrations were monitored and CYP2C19 (*2) and CYP2D6 genotype (*3, *4, *5, *6, *9, *10, *41 and gene duplication) were obtained, yielding graded allele-specific CYP2D6 patient groups.
|
17667959 |
2008 |
Major Depressive Disorder
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications.
|
21861666 |
2011 |
Major Depressive Disorder
|
0.360 |
Biomarker
|
disease |
PSYGENET |
CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications.
|
21861666 |
2011 |
Major Depressive Disorder
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder.
|
24014145 |
2013 |
Major Depressive Disorder
|
0.360 |
Biomarker
|
disease |
PSYGENET |
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.
|
23081704 |
2013 |
Major Depressive Disorder
|
0.360 |
Biomarker
|
disease |
PSYGENET |
The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder.
|
24014145 |
2013 |
Major Depressive Disorder
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.
|
26343256 |
2015 |
Major Depressive Disorder
|
0.360 |
Biomarker
|
disease |
BEFREE |
In humans, we found that the absence of CYP2C19 was associated with a bilateral hippocampal volume increase in two independent healthy cohorts (N=386 and 1032) and a lower prevalence of major depressive disorder and depression severity in African-Americans (N=3848).
|
27895323 |
2017 |
Major Depressive Disorder
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to assess the impact of CYP2D6 and CYP2C19 variation on venlafaxine (VEN) at steady state in patients from Trinidad and Tobago of Indian and African descent with major depressive disorder.
|
29327975 |
2018 |
Major Depressive Disorder
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Our results denied the role of CYP2C19 polymorphisms for remission after venlafaxine treatment in MDD patients.
|
31842058 |
2020 |